Which DMAMS have been approved to treat in multiple sclerosis (MS)?

Updated: Oct 08, 2019
  • Author: Christopher Luzzio, MD; Chief Editor: Jasvinder Chawla, MD, MBA  more...
  • Print
Answer

Disease-modifying therapies have shown beneficial effects in patients with relapsing MS, including reduced frequency and severity of clinical attacks. These agents appear to slow the progression of disability and the reduce accumulation of lesions within the brain and spinal cord. The disease-modifying agents for MS (DMAMS) currently approved for use by the US Food and Drug Administration (FDA) include the following:

  • Interferon beta-1a (Avonex, Rebif) [6]

  • Interferon beta-1b (Betaseron, Extavia) [7]

  • Peginterferon beta-1a (Plegridy) [8]

  • Glatiramer acetate (Copaxone) [9]

  • Natalizumab (Tysabri) [10, 11]

  • Mitoxantrone [12]

  • Fingolimod (Gilenya) [13]

  • Siponimod (Mayzent) [14]

  • Teriflunomide (Aubagio) [15]

  • Dimethyl fumarate (Tecfidera) [16, 17, 18, 19]

  • Alemtuzumab (Lemtrada) [20, 21, 22]

  • Daclizumab (Zinbryta) [23, 24]

  • Ocrelizumab (Ocrevus) [23, 24]

  • Cladribine (Mavenclad) [25, 26]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!